Review





Similar Products

jnk1  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc jnk1
Rats were injected in the paw with α-FGFR3-positive serum (50 µL, diluted 1:10) or IgG depleted serum. DRG were harvested 2h after injection. ( A ) Representative immunoblots depicting levels of ERK, <t>JNK1/2,</t> and p-p38 as well as their respective phosphorylated counterparts. ( B ) Bar graph with scatter plot showing levels of phosphorylated ERK, JNK, and p38 in DRG from rats injected as indicated. Mean ± SEM, *p<0.05, Mann-Whitney test, n=6 rats per group.
Jnk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnk1/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
jnk1 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
mouse anti jnk1  (Santa Cruz Biotechnology)
95
Santa Cruz Biotechnology mouse anti jnk1
Rats were injected in the paw with α-FGFR3-positive serum (50 µL, diluted 1:10) or IgG depleted serum. DRG were harvested 2h after injection. ( A ) Representative immunoblots depicting levels of ERK, <t>JNK1/2,</t> and p-p38 as well as their respective phosphorylated counterparts. ( B ) Bar graph with scatter plot showing levels of phosphorylated ERK, JNK, and p38 in DRG from rats injected as indicated. Mean ± SEM, *p<0.05, Mann-Whitney test, n=6 rats per group.
Mouse Anti Jnk1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti jnk1/product/Santa Cruz Biotechnology
Average 95 stars, based on 1 article reviews
mouse anti jnk1 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti p jnk1 2  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc anti p jnk1 2
Rats were injected in the paw with α-FGFR3-positive serum (50 µL, diluted 1:10) or IgG depleted serum. DRG were harvested 2h after injection. ( A ) Representative immunoblots depicting levels of ERK, <t>JNK1/2,</t> and p-p38 as well as their respective phosphorylated counterparts. ( B ) Bar graph with scatter plot showing levels of phosphorylated ERK, JNK, and p38 in DRG from rats injected as indicated. Mean ± SEM, *p<0.05, Mann-Whitney test, n=6 rats per group.
Anti P Jnk1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti p jnk1 2/product/Cell Signaling Technology Inc
Average 97 stars, based on 1 article reviews
anti p jnk1 2 - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
anti jnk1 antibody  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc anti jnk1 antibody
(A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of <t>JNK1</t> (p-JNK1) and total JNK1 in untreated (DMSO) and FK506-treated (2 μM, 45 min) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the FK506 treatment relative to the untreated condition (DMSO) shown in (A). (D-F) Western-blot analysis (D) and quantification (E, F) of cyclosporin A (CsA)-treated (2 μM, 45 min) neurons. (G-I) Western-blot analysis (G) and quantification (H, I) of ascomycin-treated (2 μM, 45 min) neurons. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4, each). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant.
Anti Jnk1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti jnk1 antibody/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
anti jnk1 antibody - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti phospho jnk1 antibody  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc anti phospho jnk1 antibody
(A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of <t>JNK1</t> <t>(p-JNK1)</t> and total JNK1 in untreated (DMSO) and FK506-treated (2 μM, 45 min) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the FK506 treatment relative to the untreated condition (DMSO) shown in (A). (D-F) Western-blot analysis (D) and quantification (E, F) of cyclosporin A (CsA)-treated (2 μM, 45 min) neurons. (G-I) Western-blot analysis (G) and quantification (H, I) of ascomycin-treated (2 μM, 45 min) neurons. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4, each). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant.
Anti Phospho Jnk1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho jnk1 antibody/product/Cell Signaling Technology Inc
Average 97 stars, based on 1 article reviews
anti phospho jnk1 antibody - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier

Image Search Results


Rats were injected in the paw with α-FGFR3-positive serum (50 µL, diluted 1:10) or IgG depleted serum. DRG were harvested 2h after injection. ( A ) Representative immunoblots depicting levels of ERK, JNK1/2, and p-p38 as well as their respective phosphorylated counterparts. ( B ) Bar graph with scatter plot showing levels of phosphorylated ERK, JNK, and p38 in DRG from rats injected as indicated. Mean ± SEM, *p<0.05, Mann-Whitney test, n=6 rats per group.

Journal: bioRxiv

Article Title: Direct Binding of FGFR3 Autoantibodies to Sensory Neurons Drives Hyperexcitability and Mechanical Pain Hypersensitivity

doi: 10.1101/2025.06.01.657230

Figure Lengend Snippet: Rats were injected in the paw with α-FGFR3-positive serum (50 µL, diluted 1:10) or IgG depleted serum. DRG were harvested 2h after injection. ( A ) Representative immunoblots depicting levels of ERK, JNK1/2, and p-p38 as well as their respective phosphorylated counterparts. ( B ) Bar graph with scatter plot showing levels of phosphorylated ERK, JNK, and p38 in DRG from rats injected as indicated. Mean ± SEM, *p<0.05, Mann-Whitney test, n=6 rats per group.

Article Snippet: After transfer, the membranes were blocked at room temperature for 1 h with TBST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1 % Tween 20), 5% (mass/vol) non-fat dry milk, then incubated separately in the primary antibodies FGFR3 (Sigma, Cat#SAB5702794), p38 (Cell Signaling, Cat#8690), pp38 T180/Y182 (Cell Signaling, Cat#4511), JNK1 (Cell Signaling, Cat#3708), pJNK1 T183/Y185 (Cell Signaling, Cat#4668), ERK (Cell Signaling, Cat#4696), pERK T202/Y204 (Cell Signaling, Cat#4370), Actin (Thermo Fisher Scientific, Cat#PA116889) or βIII-Tubulin (Promega, Cat#G7121) in TBST, 5% (mass/vol) BSA, overnight at 4°C.

Techniques: Injection, Western Blot, MANN-WHITNEY

(A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (p-JNK1) and total JNK1 in untreated (DMSO) and FK506-treated (2 μM, 45 min) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the FK506 treatment relative to the untreated condition (DMSO) shown in (A). (D-F) Western-blot analysis (D) and quantification (E, F) of cyclosporin A (CsA)-treated (2 μM, 45 min) neurons. (G-I) Western-blot analysis (G) and quantification (H, I) of ascomycin-treated (2 μM, 45 min) neurons. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4, each). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant.

Journal: PLOS ONE

Article Title: Ca 2+ -PP2B-PSD-95 axis: A novel regulatory mechanism of the phosphorylation state of Serine 295 of PSD-95

doi: 10.1371/journal.pone.0313441

Figure Lengend Snippet: (A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (p-JNK1) and total JNK1 in untreated (DMSO) and FK506-treated (2 μM, 45 min) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the FK506 treatment relative to the untreated condition (DMSO) shown in (A). (D-F) Western-blot analysis (D) and quantification (E, F) of cyclosporin A (CsA)-treated (2 μM, 45 min) neurons. (G-I) Western-blot analysis (G) and quantification (H, I) of ascomycin-treated (2 μM, 45 min) neurons. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4, each). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant.

Article Snippet: The anti-PSD-95 antibody (#MA1-046) was obtained from Thermo Fisher Scientific (Asheville, NC, USA), the anti-phospho-PSD-95 (Ser295) antibody (#45737S), anti-phospho-JNK1 antibody (#9255S) and anti-JNK1 antibody (#3708S) from Cell Signaling Technology (Danvers, MA, USA), and the anti-GSK3β antibody (#sc-81462) and anti-phospho-GSK3β (S9) antibody (#sc-373800) from Santa Cruz Biotechnology.

Techniques: Western Blot, Standard Deviation

(A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (pJNK1) and total JNK1 in untreated (control) and EGTA-treated (2.5 mM, 1 h) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the EGTA treatment relative to the untreated condition (control) shown in (A). The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant. (D, E) Pretreatment by EGTA (2.5 mM, 45 min) before CsA treatment (2 μM, 45 min) occluded the effect of CsA. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4 from two independent experiments). *** P < 0.001 by two-way ANOVA with the post-hoc Tukey’s multiple comparison test; n.s., not significant. F (1,12) = 68.97, P < 0.0001 for EGTA, F (1,12) = 211.5, P < 0.0001 for CsA, and F (1,12) = 69.50, P < 0.0001 for interaction.

Journal: PLOS ONE

Article Title: Ca 2+ -PP2B-PSD-95 axis: A novel regulatory mechanism of the phosphorylation state of Serine 295 of PSD-95

doi: 10.1371/journal.pone.0313441

Figure Lengend Snippet: (A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (pJNK1) and total JNK1 in untreated (control) and EGTA-treated (2.5 mM, 1 h) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the EGTA treatment relative to the untreated condition (control) shown in (A). The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant. (D, E) Pretreatment by EGTA (2.5 mM, 45 min) before CsA treatment (2 μM, 45 min) occluded the effect of CsA. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4 from two independent experiments). *** P < 0.001 by two-way ANOVA with the post-hoc Tukey’s multiple comparison test; n.s., not significant. F (1,12) = 68.97, P < 0.0001 for EGTA, F (1,12) = 211.5, P < 0.0001 for CsA, and F (1,12) = 69.50, P < 0.0001 for interaction.

Article Snippet: The anti-PSD-95 antibody (#MA1-046) was obtained from Thermo Fisher Scientific (Asheville, NC, USA), the anti-phospho-PSD-95 (Ser295) antibody (#45737S), anti-phospho-JNK1 antibody (#9255S) and anti-JNK1 antibody (#3708S) from Cell Signaling Technology (Danvers, MA, USA), and the anti-GSK3β antibody (#sc-81462) and anti-phospho-GSK3β (S9) antibody (#sc-373800) from Santa Cruz Biotechnology.

Techniques: Western Blot, Control, Standard Deviation, Comparison

(A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (p-JNK1) and total JNK1 in untreated (DMSO) and FK506-treated (2 μM, 45 min) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the FK506 treatment relative to the untreated condition (DMSO) shown in (A). (D-F) Western-blot analysis (D) and quantification (E, F) of cyclosporin A (CsA)-treated (2 μM, 45 min) neurons. (G-I) Western-blot analysis (G) and quantification (H, I) of ascomycin-treated (2 μM, 45 min) neurons. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4, each). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant.

Journal: PLOS ONE

Article Title: Ca 2+ -PP2B-PSD-95 axis: A novel regulatory mechanism of the phosphorylation state of Serine 295 of PSD-95

doi: 10.1371/journal.pone.0313441

Figure Lengend Snippet: (A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (p-JNK1) and total JNK1 in untreated (DMSO) and FK506-treated (2 μM, 45 min) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the FK506 treatment relative to the untreated condition (DMSO) shown in (A). (D-F) Western-blot analysis (D) and quantification (E, F) of cyclosporin A (CsA)-treated (2 μM, 45 min) neurons. (G-I) Western-blot analysis (G) and quantification (H, I) of ascomycin-treated (2 μM, 45 min) neurons. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4, each). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant.

Article Snippet: The anti-PSD-95 antibody (#MA1-046) was obtained from Thermo Fisher Scientific (Asheville, NC, USA), the anti-phospho-PSD-95 (Ser295) antibody (#45737S), anti-phospho-JNK1 antibody (#9255S) and anti-JNK1 antibody (#3708S) from Cell Signaling Technology (Danvers, MA, USA), and the anti-GSK3β antibody (#sc-81462) and anti-phospho-GSK3β (S9) antibody (#sc-373800) from Santa Cruz Biotechnology.

Techniques: Western Blot, Standard Deviation

(A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (pJNK1) and total JNK1 in untreated (control) and EGTA-treated (2.5 mM, 1 h) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the EGTA treatment relative to the untreated condition (control) shown in (A). The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant. (D, E) Pretreatment by EGTA (2.5 mM, 45 min) before CsA treatment (2 μM, 45 min) occluded the effect of CsA. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4 from two independent experiments). *** P < 0.001 by two-way ANOVA with the post-hoc Tukey’s multiple comparison test; n.s., not significant. F (1,12) = 68.97, P < 0.0001 for EGTA, F (1,12) = 211.5, P < 0.0001 for CsA, and F (1,12) = 69.50, P < 0.0001 for interaction.

Journal: PLOS ONE

Article Title: Ca 2+ -PP2B-PSD-95 axis: A novel regulatory mechanism of the phosphorylation state of Serine 295 of PSD-95

doi: 10.1371/journal.pone.0313441

Figure Lengend Snippet: (A) Western-blot analyses of phosphorylated Ser295 of PSD-95 (pS295), total PSD-95, an active form of JNK1 (pJNK1) and total JNK1 in untreated (control) and EGTA-treated (2.5 mM, 1 h) primary mouse cortical neurons. (B, C) Quantification of pS295/PSD-95 (B) and pJNK1/JNK1 (C) with the EGTA treatment relative to the untreated condition (control) shown in (A). The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4). *** P < 0.001 by the unpaired Student’s t -test; n.s., not significant. (D, E) Pretreatment by EGTA (2.5 mM, 45 min) before CsA treatment (2 μM, 45 min) occluded the effect of CsA. The data are represented as the mean ± standard deviation overlaid with individual data points (n = 4 from two independent experiments). *** P < 0.001 by two-way ANOVA with the post-hoc Tukey’s multiple comparison test; n.s., not significant. F (1,12) = 68.97, P < 0.0001 for EGTA, F (1,12) = 211.5, P < 0.0001 for CsA, and F (1,12) = 69.50, P < 0.0001 for interaction.

Article Snippet: The anti-PSD-95 antibody (#MA1-046) was obtained from Thermo Fisher Scientific (Asheville, NC, USA), the anti-phospho-PSD-95 (Ser295) antibody (#45737S), anti-phospho-JNK1 antibody (#9255S) and anti-JNK1 antibody (#3708S) from Cell Signaling Technology (Danvers, MA, USA), and the anti-GSK3β antibody (#sc-81462) and anti-phospho-GSK3β (S9) antibody (#sc-373800) from Santa Cruz Biotechnology.

Techniques: Western Blot, Control, Standard Deviation, Comparison